Hamel R, Masson P, Ford-Hutchinson A W, Jones T R, Brunet G, Piechuta H
Prostaglandins. 1982 Sep;24(3):419-32. doi: 10.1016/0090-6980(82)90168-x.
Leukotriene D4 (LTD4) when administered intravenously or by aerosol to guinea pigs produced changes in pulmonary mechanics including a decrease in dynamic compliance and an increase in pulmonary resistance. The effects of intravenous LTD4 (0.5 microgram kg-1) were short lived and abolished by pretreatment of the animal with either cyclooxygenase inhibitors, a thromboxane synthetase inhibitor (OKY 1555) or an SRS-A antagonist (FPL 55712). These findings suggest that bronchoconstriction produced by the intravenous infusion of LTD4 at 0.5 microgram kg-1 is due to the release of thromboxane A2. However, in animals treated with indomethacin, LTD4 at higher doses (greater than 0.8 microgram kg-1) still elicited a bronchoconstriction which could be blocked by FPL 55712. Nebulization of 0.1 - 1.0 microgram of LTD4 into the lung produced prolonged changes in pulmonary mechanics which were inhibited by FPL 55712 and were potentiated by indomethacin. LTD4, therefore, when administered by aerosol produced effects on the lung which were not mediated by cyclooxygenase products. Responses to nebulized rather than intravenous LTD4 in the guinea pig may more closely resemble those seen in human tissues.
当给豚鼠静脉注射或雾化吸入白三烯D4(LTD4)时,会引起肺力学变化,包括动态顺应性降低和肺阻力增加。静脉注射LTD4(0.5微克/千克)的作用持续时间短,用环氧化酶抑制剂、血栓素合成酶抑制剂(OKY 1555)或SRS - A拮抗剂(FPL 55712)预处理动物可消除这些作用。这些发现表明,以0.5微克/千克静脉输注LTD4所产生的支气管收缩是由于血栓素A2的释放。然而,在用吲哚美辛治疗的动物中,较高剂量(大于0.8微克/千克)的LTD4仍会引起支气管收缩,而FPL 55712可阻断这种收缩。将0.1 - 1.0微克LTD4雾化吸入肺内会引起肺力学的长期变化,这种变化可被FPL 55712抑制,并被吲哚美辛增强。因此,雾化吸入LTD4对肺产生的作用不是由环氧化酶产物介导的。豚鼠对雾化而非静脉注射LTD4的反应可能更类似于在人体组织中观察到的反应。